Trial record 2 of 30 for:    Avanir

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03338920
Recruitment Status : Recruiting
First Posted : November 9, 2017
Last Update Posted : May 24, 2018
Information provided by (Responsible Party):
Avanir Pharmaceuticals

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2019
  Estimated Study Completion Date : November 2019